US Treasury plans rules for China pharma deals
New regulations would likely permit most licensing agreements, with exceptions for sensitive biotechnology.
AI-assisted coverage comparison, editor-supervised · How this was made
Photograph: Seeking Alpha (embedded from source)
What this story says
- The U.S. Treasury Department is formulating rules for biopharma companies investing in China.
- The proposed rules would likely permit most licensing deals for drugs originating in China.
- Exceptions may apply to deals involving weaponizable biotechnology or pathogens.
- Some U.S. pharmaceutical leaders favour fewer restrictions, while others urge caution.
Who covered it
Percentages are shares of the 6 outlets carrying a published leaning rating. 5 of the 11 outlets we know ran this story carry no rating and are not counted in them. Coverage measured .
Trust
50/100
Craft
45/100
Hype
20/100
11 sources · methodology
Thin on the left so far
None of the 6 outlets with a published leaning rating that ran this story are rated left.
This story is still being watched, so it is a count and not yet a finding. Coverage keeps arriving for hours after an event, and a side that has published nothing this morning may publish by tonight. If it is still true when we stop checking, we will say so plainly.
The U.S. Treasury Department is formulating rules that would govern biopharmaceutical companies investing in China. These regulations are expected to allow the majority of licensing deals for drugs that originate in China. The rules may include exceptions for deals involving weaponizable biotechnology or pathogens, according to three sources familiar with the matter who spoke to Reuters.
Divergent views on China investment
Within the U.S. pharmaceutical industry, there are differing opinions on the extent of restrictions that should be placed on investments and collaborations with China. Leaders such as the CEO of Pfizer have expressed opposition to broad restrictions, stating they foresee no security threat in most collaborations. Conversely, some executives from smaller biotechnology firms have voiced concerns about strategic reliance on China and are advocating for increased caution.
What the coverage left out
None of the centre- or right-rated reports mention the specific reasons why U.S. and European drugmakers are increasingly collaborating with Chinese biopharma companies, such as seeking access to innovative medicines to replenish pipelines ahead of patent expirations on major drugs, as reported by Reuters in its full report.
Still developing. We have re-checked which outlets are covering this 1 time, most recently on 18 Sept 2026, 21:15, and will add the sides that appear.
How each side covered it
Our own reading of the reporting listed below, written from the outlets’ articles rather than quoted from them. The reasoning is set out on our methodology page.
Left
0 rated outlets
No outlet rated left has run this story so far. We are still checking, and will say plainly if that does not change.
Centre
3 rated outlets
- Centre-rated reports led on the U.S. Treasury Department's formulation of rules for biopharma companies investing in China. These reports noted that the rules would likely preserve the ability to complete most licensing deals for drugs originating in the country. They also mentioned potential exceptions for weaponizable biotechnology or pathogens. The reports carried information from Reuters, citing three sources briefed on the process.
Right
3 rated outlets
- Right-rated reports focused on the U.S. weighing the allowance of most pharmaceutical licensing deals with China, citing sources. These reports indicated that the U.S. is working on rules for pharmaceutical companies investing in China that would likely preserve their ability to strike most licensing deals for Chinese drugs. They noted this would represent a departure from previous policies of hardening trade relations with China in other sectors. The reports also included commentary from Pfizer's CEO opposing broad restrictions and smaller biotech executives urging caution.
Questions about this coverage
- How did the left and right cover US Treasury plans rules for China pharma deals?
- Of the 6 outlets on this story carrying a published leaning rating, 0% are rated left, 50% are rated centre, 50% are rated right. Those percentages are shares of the rated outlets, not of every outlet that ran it, which was 11. The sections above set out what each side emphasised, in its own terms.
- Is US Treasury plans rules for China pharma deals left or right?
- Too few of the outlets on this story carry a published leaning rating to say. 6 of them do, and this site does not characterise a field under 12: at that size one newsroom filing moves the share by ten points. The percentages above are the count as it stands.
- Is the coverage of US Treasury plans rules for China pharma deals biased?
- US Treasury plans rules for China pharma deals is one event reported by 11 outlets, and this page does not rate the story as biased or unbiased. What it publishes is the spread: which outlets ran it, where named rating organisations place each of them on the spectrum, and what each side chose to lead with. A leaning rating describes an outlet's record over time, not this article, and the two should not be run together.
- Which side is not reporting US Treasury plans rules for China pharma deals?
- When we first saw this story, outlets rated left had barely covered it. Coverage accretes for hours after an event, so that is where to look rather than a verdict — the split above is the current count, and it is the one to read.
- Which outlets covered US Treasury plans rules for China pharma deals?
- 11 that we know of, every one of them listed further up this page with a link to its own report and to what we hold on the publisher. Nothing here is a summary of somebody else's summary: the outlets are named so the original reporting can be read.
- What are the proposed U.S. rules for biopharma companies investing in China?
- The U.S. Treasury Department is formulating rules that are expected to allow most licensing deals for drugs originating in China. However, exceptions may be made for deals involving weaponizable biotechnology or pathogens, according to sources familiar with the matter.
- What are the differing views among U.S. pharma leaders regarding China investments?
- Some leaders, like Pfizer's CEO, oppose broad restrictions and see no security threat in collaborations. Others, particularly from smaller biotech firms, express concern about strategic reliance on China and advocate for caution.
- Which types of deals might be restricted under the new U.S. rules?
- The proposed rules are expected to allow most licensing deals for drugs originating in China. Potential restrictions could apply to agreements involving weaponizable biotechnology or pathogens, reflecting national security concerns.
Read it at the source
11 outlets, grouped by the leaning a published rating gives them. Every headline links to the original; an underlined outlet name opens our profile of that publisher.
Left
0No outlet in this group ran the story.
Centre
3- Pharmalittle: We're reading about licensing deals with China, making drugs in space, and more (opens STAT in a new tab)
- Exclusive-US weighs allowing most pharma licensing deals with China, sources say (opens WTVB in a new tab)
- EXCLUSIVE: US weighs allowing most pharma licensing deals with China, sources say (opens Reuters in a new tab)
Right
3- Exclusive-US weighs allowing most pharma licensing deals with China, sources say - Regional Media News (opens regionalmedianews.com in a new tab)
regionalmedianews.com — is regionalmedianews.com biased? Our profile of this outlet
- U.S. Estimates Allow Most Pharmaceutical Licensing Agreements with China, Sources Say (opens Globo in a new tab)
- U.S. weighs allowing most pharma licensing deals with China (opens Seeking Alpha in a new tab)
Seeking Alpha — is Seeking Alpha biased? Our profile of this outlet
Not rated
5- US Treasury Department drafts rules to keep most pharma licensing deals with China alive (opens Crypto Briefing in a new tab)
Crypto Briefing — is Crypto Briefing biased? Our profile of this outlet
- US Treasury Department drafts rules to keep most pharma licensing deals with China alive (opens Cryptocurrency News in a new tab)
Cryptocurrency News — is Cryptocurrency News biased? Our profile of this outlet
- US weighs allowing most pharma licensing deals with China (opens OODA Loop in a new tab)
- Chinese Biotech, Towards New Rules for US Companies? Indiscretions (opens Formiche.net in a new tab)
Formiche.net — is Formiche.net biased? Our profile of this outlet
- US: Expanding Pharmaceutical Licensing Agreements with China Under Consideration (opens iatronet.gr in a new tab)
iatronet.gr — is iatronet.gr biased? Our profile of this outlet
How did this read?
About the coverage, not about the story. We do not ask whether you agree with what happened — we have no honest use for that answer.
